The dual inhibitors Metavert (inhibitor of GSK3B and HDACs) or CUDC-907 (Phosphoinositide 3-kinases/HDAC Inhibitor) and the HDAC inhibitor AES-135 have shown antitumor activity in mouse models of pancreatic cancer [34–36]. Here, HDAC9 is linked to pancreatic neoplasm.